Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population

Human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfection is common in people who inject drugs (PWIDs). Recently, ‘high‐risk’ behaviour among men who have sex with men (MSM) has emerged as another main route of HCV transmission. We analysed temporal trends in HCV epidemiology in a cohort of Viennese HIV+ patients.

[1]  T. Szekeres,et al.  Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication. , 2019, AIDS patient care and STDs.

[2]  C. Latkin,et al.  Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore. , 2019, Journal of substance abuse treatment.

[3]  M. Trauner,et al.  High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients , 2019, United European gastroenterology journal.

[4]  C. Leen,et al.  Establishing a hepatitis C continuum of care among HIV/hepatitis C virus‐coinfected individuals in EuroSIDA , 2019, HIV medicine.

[5]  J. Ward,et al.  The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals , 2019, Journal of virus eradication.

[6]  J. Castilla,et al.  Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain , 2018, PloS one.

[7]  K. Farmer,et al.  National estimates of case-mix, mortality, and economic outcomes among inpatient HIV/AIDS mono-infection and hepatitis C co-infection cases in the US. , 2018, Journal of evaluation in clinical practice.

[8]  D. Y. Kim.  Efficacy of Direct-Acting Antivirals in Patients with Hepatitis C Virus/Human Immunodeficiency Virus Coinfection: A Gap between Clinical Trial and Real Practice , 2018, Gut and liver.

[9]  J. Lazarus,et al.  The removal of DAA restrictions in Europe - One step closer to eliminating HCV as a major public health threat. , 2018, Journal of hepatology.

[10]  S. Mohanty,et al.  Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting , 2018, Gut and liver.

[11]  O. Laeyendecker,et al.  Prevalence and mapping of hepatitis C infections among men who have sex with men in New York City , 2018, PloS one.

[12]  B. Hoen,et al.  Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV , 2018, AIDS.

[13]  B. Haire,et al.  The new MTV generation: Using methamphetamine, Truvada™, and Viagra™ to enhance sex and stay safe. , 2018, The International journal on drug policy.

[14]  J. Losa,et al.  All‐oral direct‐acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV–coinfected subjects in real‐world practice: Madrid coinfection registry findings , 2018, Hepatology.

[15]  J. Rockstroh,et al.  Rates of sustained virological response 12 weeks after the scheduled end of direct‐acting antiviral (DAA)‐based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? , 2018, HIV medicine.

[16]  J. Lazarus,et al.  Hepatitis C: The beginning of the end—key elements for successful European and national strategies to eliminate HCV in Europe , 2018, Journal of viral hepatitis.

[17]  S. McCormack,et al.  Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV‐positive persons version 9.0 , 2018, HIV medicine.

[18]  S. Saab,et al.  Hepatitis C and human immunodeficiency virus coinfection in the era of direct‐acting antiviral agents: No longer a difficult‐to‐treat population , 2018, Hepatology.

[19]  M. Gschwantler,et al.  Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct‐acting antivirals , 2018, Journal of viral hepatitis.

[20]  A. Nardone,et al.  Sexualized drug use (‘chemsex’) and high‐risk sexual behaviours in HIV‐positive men who have sex with men , 2018, HIV medicine.

[21]  J. Leung,et al.  Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review , 2017, The Lancet. Global health.

[22]  J. Roberson,et al.  Comparison of the Hepatitis C Continua of Care Between Hepatitis C Virus/HIV Coinfected and Hepatitis C Virus Mono-Infected Patients in Two Treatment Eras During 2008-2015. , 2017, AIDS research and human retroviruses.

[23]  J. Kort,et al.  No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir , 2017, Antimicrobial Agents and Chemotherapy.

[24]  M. Trauner,et al.  Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients , 2017, Wiener klinische Wochenschrift.

[25]  J. Pineda,et al.  HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study , 2017, HIV clinical trials.

[26]  M. Manns,et al.  Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. , 2017, The lancet. Gastroenterology & hepatology.

[27]  P. Schwabl,et al.  Letter: sustained virological response and liver healing – authors' reply , 2017, Alimentary pharmacology & therapeutics.

[28]  Gamal Esmat,et al.  Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. , 2017, The lancet. Gastroenterology & hepatology.

[29]  M. Trauner,et al.  Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna , 2017, Wiener klinische Wochenschrift.

[30]  W. Bernardo,et al.  Seroprevalence of hepatitis C virus among people living with HIV/AIDS in Latin America and the Caribbean: a systematic review , 2016, BMC Infectious Diseases.

[31]  Reza Assadi,et al.  The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 , 2016, The Lancet.

[32]  M. Mckee,et al.  Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees , 2016, The Lancet.

[33]  P. Easterbrook,et al.  Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. , 2016, The Lancet. Infectious diseases.

[34]  M. Gschwantler,et al.  Direct Observed Therapy of Chronic Hepatitis C With Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility—a New Concept for Treatment of Patients With Borderline Compliance Receiving Opioid Substitution Therapy , 2016, The American Journal of Gastroenterology.

[35]  P. Schwabl,et al.  Advances in the management of HIV/HCV coinfection , 2016, Hepatology International.

[36]  S. Torres-Rueda,et al.  Illicit drug use in sexual settings (‘chemsex’) and HIV/STI transmission risk behaviour among gay men in South London: findings from a qualitative study , 2015, Sexually Transmitted Infections.

[37]  T. Reiberger.  Chronic hepatitis C: treat everyone now or stratify by disease? , 2015, Minerva gastroenterologica e dietologica.

[38]  M. Trauner,et al.  Revisiting liver disease progression in HIV/HCV‐coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3 , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[39]  A. Rieger,et al.  Health‐related quality of life and severity of fatigue in HIV/HCV co‐infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[40]  A. Rieger,et al.  Revisiting predictors of virologic response to PEGIFN + RBV therapy in HIV‐/HCV‐coinfected patients: the role of metabolic factors and elevated GGT levels , 2014, Journal of viral hepatitis.

[41]  A. Rieger,et al.  Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV–hepatitis C virus coinfected patients , 2013, AIDS.

[42]  Louisa Degenhardt,et al.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews , 2011, The Lancet.

[43]  M. Heo,et al.  Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. , 2011, Drug and alcohol dependence.

[44]  A. Rieger,et al.  HIV–HCV co‐infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension , 2009, Journal of viral hepatitis.

[45]  A. Rieger,et al.  Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co‐infection , 2008, European journal of clinical investigation.

[46]  T. Berg,et al.  Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. , 2019, Gastroenterology.